Literature DB >> 26540372

Short- and long-term outcomes of endoscopic resection of rectal neuroendocrine tumours: analyses according to the WHO 2010 classification.

Kazuhiko Nakamura1, Mikako Osada2, Ayako Goto1, Tsutomu Iwasa1, Shunsuke Takahashi2, Nobuyoshi Takizawa2, Kazuya Akahoshi3, Toshiaki Ochiai4, Norimoto Nakamura5, Hirotada Akiho6, Soichi Itaba7, Naohiko Harada8, Moritomo Iju9, Munehiro Tanaka10, Hiroaki Kubo11, Shinichi Somada12, Eikichi Ihara1, Yoshinao Oda2, Tetsuhide Ito1, Ryoichi Takayanagi1.   

Abstract

OBJECTIVE: Although the World Health Organisation (WHO) defined a novel classification of gastroenteropancreatic neuroendocrine tumours (NETs) in 2010, indications for endoscopic resection of rectal NETs in the guidelines were based on evidence accumulated for carcinoid tumours defined by a previous classification. This study was designed to clarify indications for endoscopic resection of rectal NETs corresponding to the new WHO classifications.
MATERIAL AND METHODS: One hundred-seventy rectal NETs resected endoscopically from April 2001 to March 2012 were histologically re-classified according to the WHO 2010 criteria. The clinicopathological features of these lesions were analysed, and the short- and long-term outcomes of endoscopic resection were evaluated.
RESULTS: Of the 170 rectal NETs, 166 were histopathologically diagnosed as NET G1 and four as NET G2. Thirty-eight tumours (22.4%) were positive for lymphovascular invasion, a percentage higher than expected. Although the curative resection rate was low (65.3%), en bloc (98.8%) and complete (85.9%) resection rates were high. Modified endoscopic mucosal resection (88.0%) and endoscopic submucosal dissection (92.2%) resulted in significantly higher complete resection rates than conventional endoscopic mucosal resection (36.4%). No patient experienced tumour recurrence, despite the low curative resection rate.
CONCLUSION: Despite the low curative resection rate, prognosis after endoscopic resection of rectal NETs was excellent. Prospective large-scale, long-term studies are required to determine whether NET G2 and tumours >1 cm should be included in the indication for endoscopic resection and whether tumours with lymphovascular invasion can be followed up without additional surgery.

Entities:  

Keywords:  Endoscopic resection; indication; outcome; rectal neuroendocrine tumour

Mesh:

Year:  2015        PMID: 26540372     DOI: 10.3109/00365521.2015.1107752

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

Review 1.  Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Günter Klöppel; Stefano La Rosa
Journal:  Virchows Arch       Date:  2017-11-13       Impact factor: 4.064

2.  Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE).

Authors:  Caroline Fine; Guillaume Roquin; Eric Terrebonne; Thierry Lecomte; Romain Coriat; Christine Do Cao; Louis de Mestier; Elise Coffin; Guillaume Cadiot; Patricia Nicolli; Vincent Lepiliez; Vincent Hautefeuille; Jeanne Ramos; Paul Girot; Sophie Dominguez; Fritz-Line V Céphise; Julien Forestier; Valérie Hervieu; Mathieu Pioche; Thomas Walter
Journal:  United European Gastroenterol J       Date:  2019-07-04       Impact factor: 4.623

3.  Neuroendocrine Tumors of the Large Intestine: Clinicopathological Features and Predictive Factors of Lymph Node Metastasis.

Authors:  Motohiro Kojima; Koji Ikeda; Norio Saito; Naoki Sakuyama; Kenichi Koushi; Shingo Kawano; Toshiaki Watanabe; Kenichi Sugihara; Masaaki Ito; Atsushi Ochiai
Journal:  Front Oncol       Date:  2016-07-18       Impact factor: 6.244

4.  Lymphovascular invasion in more than one-quarter of small rectal neuroendocrine tumors.

Authors:  Mi Jung Kwon; Ho Suk Kang; Jae Seung Soh; Hyun Lim; Jong Hyeok Kim; Choong Kee Park; Hye-Rim Park; Eun Sook Nam
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

5.  The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure.

Authors:  Yoichiro Okubo; Osamu Motohashi; Norisuke Nakayama; Ken Nishimura; Rika Kasajima; Yohei Miyagi; Manabu Shiozawa; Emi Yoshioka; Masaki Suzuki; Kota Washimi; Kae Kawachi; Madoka Nito; Yoichi Kameda; Tomoyuki Yokose
Journal:  Diagn Pathol       Date:  2016-11-08       Impact factor: 2.644

6.  Two Cases of Rectal Neuroendocrine Tumor Resection Combined with Dissection of the Circular Muscle Layer Using the Endoscopic Submucosal Dissection Technique.

Authors:  Kumpei Honjo; Kazumasa Kure; Ryosuke Ichikawa; Hisashi Ro; Rina Takahashi; Koichiro Niwa; Shun Ishiyama; Kiichi Sugimoto; Hirohiko Kamiyama; Makoto Takahashi; Yutaka Kojima; Michitoshi Goto; Yuichi Tomiki; Kazuhiro Sakamoto; Yuki Fukumura; Takashi Yao
Journal:  Case Rep Gastroenterol       Date:  2016-11-21

7.  Risk factors associated with the progression and metastases of hindgut neuroendocrine tumors: a retrospective study.

Authors:  Yoichiro Okubo; Rika Kasajima; Masaki Suzuki; Yohei Miyagi; Osamu Motohashi; Manabu Shiozawa; Emi Yoshioka; Kota Washimi; Kae Kawachi; Yoichi Kameda; Tomoyuki Yokose
Journal:  BMC Cancer       Date:  2017-11-16       Impact factor: 4.430

Review 8.  Diagnosis and Management of Rectal Neuroendocrine Tumors.

Authors:  Shreya Chablaney; Zachary A Zator; Nikhil A Kumta
Journal:  Clin Endosc       Date:  2017-11-30

9.  Rectal Neuroendocrine Tumor G1 with a Solitary Hepatic Metastatic Lesion.

Authors:  Kohei Nagata; Kazuto Tajiri; Seitarou Shimada; Takayuki Ando; Ayumu Hosokawa; Koshi Matsui; Joji Imura; Toshiro Sugiyama
Journal:  Intern Med       Date:  2017-02-01       Impact factor: 1.271

10.  Comparison between cap-assisted and ligation-assisted endoscopic mucosal resection for rectal neuroendocrine tumors.

Authors:  Jin Lee; Yong Eun Park; Joon Hyuk Choi; Nae-Yun Heo; Jongha Park; Seung Ha Park; Young Soo Moon; Kyung Han Nam; Tae Oh Kim
Journal:  Ann Gastroenterol       Date:  2020-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.